RIBS V. Fernando Alfonso MD, PhD, FESC Hospital Universitario La Princesa Madrid.
|
|
|
- Stella Wilkerson
- 9 years ago
- Views:
Transcription
1 A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal In-Stent Restenosis: The RIBS V Clinical Trial Fernando Alfonso MD, PhD, FESC Hospital Universitario La Princesa Madrid. On Behalf of the RIBS V Investigators (Coordinator Center: Hospital Universitario Clínico San Carlos. Madrid)
2 DISCLOSURE Nothing to disclose
3 Background: Treatment of patients with BMS-ISR remains a challenge In this setting, DES provide better results than classical coronary interventions (BA, BMS, Brachytherapy). Drug-eluting balloons (DEB) are also very effective in patients with BMS-ISR, with results superior to those obtained by conventional BA and equivalent to those seen with 1 st Generation DES However, the value of DEB compared with 2 nd Generation DES in patients with BMS-ISR remains unknown
4 Objective: We sought to compare the efficacy of EES vs DEB in patients with BMS-ISR
5 RIBS V: (Restenosis Intra-stent: DEB vs EES) Multicenter, Prospective, Randomized Steering Committee. QCA & Clinical Events Committee Under the Auspices PCI WG Sociedad Española Cardiología Coordinator Center : HU Clínico San Carlos. Madrid ALICANTE H General U. 2.- ALMERIA H U Torrecardenas. 3.- ASTURIAS H U Central Asturias. 4.- BADAJOZ H U Infanta Cristina. 5.- BALEARES. H U Son Espases. 6.- BARCELONA H U Bellvitge. 7.- BARCELONA H U Clinico. 8.- BARCELONA H U Santa Cruz y San Pablo. 9.- BARCELONA H U Valle de Hebrón CANTABRIA H U Marques de Valdecilla CORUÑA H U Juan Canalejo GRANADA H U Virgen de las Nieves MADRID H U Doce de Octubre MADRID H U (la) Paz MADRID H U (la) Princesa 16.- MADRID H U Puerta de Hierro MADRID H U Clínico San Carlos MALAGA H U Carlos Haya 19.- MALAGA H U Virgen de la Victoria NAVARRA H U Provincial Navarra. 21. TOLEDO. H U Virgen de la Salud Toledo 22.- VALENCIA H Clinico U VALENCIA H General U VIGO H U Meixoeiro. Pontevedra 25.- ZARAGOZA H U. Miguel Servet. Investigators Driven Initiative Unrestricted Grants: B. Braun Surgical & Abbott Vascular
6 RIBS V: (Restenosis Intra-stent: DEB vs EES) Multicenter, Prospective, Randomized Coordinating Center: Hospital Universitario Clínico San Carlos. Madrid. Steering Committee: F. Alfonso (Chairman and Principal Investigator), J. Zueco, A. Cequier, C. Morís, C. Macaya. Clinical Events Committee: R. Hernández, M. Sabaté, C. Saenz de la Calzada. Coronary Angiography Core Laboratory: (Hospital Universitario Clinico San Carlos, Madrid) A. Cárdenas, M.J. Pérez-Vizcayno. Data Coordination, Safety Monitoring and Statistical Committee: M.J. Pérez-Vizcayno, C. Fernández. Intravascular Ultrasound and Optical Coherence Tomography Committee: N. Gonzalo, F. Alfonso. Sites and Investigators: In order of enrollment: 1 Hospital Universitario Clínico San Carlos, Madrid, (F. Alfonso, P. Jiménez-Quevedo, N. Gonzalo, J. Escaned, A. Fernández-Ortiz, C. Macaya); 2 Hospital Universitario Vall d Hebron, Barcelona, (B. García del Blanco); 3 Hospital Universitario de la Princesa, Madrid, (B. Seidelberger), 4 Complejo Hospitalario Universitario de Vigo, Vigo, (A. Iñiguez); 5 Hospital Universitario de Torrecárdenas, Almería, (M. Gómez-Recio), 6 Hospital Universitario Clinic de Barcelona, Barcelona, (M. Masotti), 7 Hospital Universitario 12 de Octubre, Madrid, (T. Velazquez), 8 Hospital Universitario Clínico de Valencia, Valencia, (J. Sanchís), 9 Hospital Universitario Puerta de Hierro, Majadahonda, (A. García-Touchard), 10 Hospital Universitario Marqués de Valdecilla, Santander, (J. Zueco), 11 Hospital Universitario Son Espases, Palma de Mallorca, (A. Bethecourt), 12 Hospital Universitario Virgen de las Nieves, Granada, (R. Melgares), 13 Hospital Universitario de Bellvitge, Barcelona, (A. Cequeir); 14 Hospital Universitario Virgen de la Victoria, Málaga, (J.M. Hernández); 15 Hospital Universitario de Alicante, Alicante, (V. Mainar); 16 Hospital Universitario Infanta Cristina. Badajoz, Badajoz, (J.R. López-Míguez); 17 Hospital Universitario Virgen de la Salud Toledo, Toledo, (J. Moreu); 18 Hospital Universitario Sant Pau, Barcelona, (V. Martí); 19 Hospital Universitario La Paz, Madrid, (R. Moreno); 20 Hospital Universitario General de Valencia, Valencia, (F. Pomar); 21 Complejo Hospitalario Universitario de Navarra, Pamplona, (R. Lezaun); 22 Hospital Universitario Carlos Haya, Malaga, (C.A. Urbano-Carrillo), 23 Hospital Universitario Miguel Servet, Zaragoza, (M.C. Ferrer-García), 24 Complejo Hospitalario Universitario de A Coruña, La Coruña, (N. Vázquez), 25 Hospitalario Universitario Central de Asturias, Oviedo, (C. Morís).
7 Inclusion / Exclusion Criteria Inclusion: Informed consent Age y BMS ISR (> 50% stenosis) Angina or silent ischemia ISR amenable for BA & Stent Exclusion: Stent Related: Stent location undefined ISR <1 Month Thrombus or TIMI 0. Vessel diameter < 2 mm ISR length > 30 mm ISR outside the Stent General: Life expectancy < 1 y Female in childbearing age Problems FU angiography Intolerance ASA/Clopidogrel LVEF < 25%
8 Sample Size Calculation EES After EES implantation: MLD: 2.6 mm RIBS I and RIBS II (1,2) Late loss: 0.3 mm (2) MLD at FU: mm DEB After DEB dilation: MLD: 2.2 mm RIBS I and RIBS II (1,2) Late loss: 0.2 mm (3) MLD at FU: Pts (86 per arm) (power 80%, alpha error 5%) 190 Pts (95 per arm) assuming a drop-out rate ~10% 1. Alfonso F. J Am Coll Cardiol 2003;42: Alfonso F. J Am Coll Cardiol. 2006;47: Unverdorben M. Circulation. 2009;119:
9 Inclusion Criteria Informed Consent RIBS V (January 2010 to January 2012) 189 Pts BMS ISR Randomization Rx Centralized Stratification: ISR Length & Edge Xience Prime (Abbott Vascular) 8 Refused Mean: 270 days 94 Pts EES 86 Pts Angio FU 100% Angiographic Success QCA Primary End-point 95 Pts DEB 84 Pts Angio FU (170 Patients: 92% of Eligible) SeQuent Please (B. Braun Surgical) 3 Died 1 Thrombosis 7 Refused Mean: 271 days
10 All (N 189) EES (N 94) DEB (N 95) Age (years) * Female 25 (13) 12 (13) 13 (14) Risk Factors Diabetes 49 (26) 19 (20) 30 (32) Hyperlipidemia 131 (69) 62 (66) 69 (73) Hypertension 136 (72) 68 (72) 68 (72) Ever smoked 126 (68) 70 (75) 56 (59) ** Family history 12 (6) 8 (9) 4 (4) * p=0.04; ** p=0.02 Clinical Data (I)
11 Clinical Data (II) All (N 189) EES (N 94) DEB (N 95) Previuos History Myocardial infarction 113 (60) 56 (60) 57 (60) Bypass surgery 11 (6) 7 (7) 4 (4) Clinical Features Unstable angina 80 (42) 42 (45) 38 (40) Stable angina 84 (44) 41 (44) 43 (45) Silent ischemia 25 (13) 11 (12) 14 (15) Time to ISR (days) 363 ( ) 350 ( ) 390 ( )
12 Angiographic Data (I) Target Vessel : All (N 189) EES (N 94) DEB (N 95) LAD 72 (38) 37 (39) 35 (37) LCX 43 (23) 22 (23) 21 (22) RCA 69 (37) 32 (34) 37 (39) SVG 5 (3) 3 (3) 2 (2) LVEF (%)
13 Angiographic Data (II) All (N 189) EES (N 94) DEB (N 95) Mehran: Ib 20 (11) 14 (15) 6 (6) Ic 46 (24) 17 (18) 29 (31) Id 6 (3) 3 (3) 3 (3) II 87 (46) 42 (45) 45 (47) III 29 (15) 17 (18) 12 (13) IV 1 (0.5) 1 (1) 0 (0) ACC/AHA B2C 99 (52) 51 (54) 48 (51)
14 Procedural Data All (N 189) EES (N 94) DEB (N 95) Initial Stent: Length of initial stent (mm) Maximal pressure (atm) Index Procedure: Maximal pressure (atm) Maximal Balloon Diam (mm) EES / DEB Length (mm) * Total inflation time (sec) 71 (45-112) 60 (30-92) 90 (60-120) ** Cross-over 8 (4) 0 (0) 8 (8) * * p<0.05 * * p=0.0001
15 3 2,5 2 1,5 1 0,5 0 RIBS V QCA: In-Segment Analysis Reference Diameter (mm) p = 0.91 EES (mm) DEB Lesion Length p = 0.96 CASS II System
16 1ry Endpoint: MLD at FU 2,5 2 1,5 MLD-FU (mm) EES DEB p < Seg Lesion 1 0,5 0 2,5 2 1,5 In-Segment MLD-FU (mm) p < Adjusted (age, smoker, stenosis, diabetes) p = ,5 0 In-Lesion
17 100 (%) Cumulative Frequency Distribution Curves PRE FU p < POST p < EES DEB 0 0 0,5 1 1,5 2 2,5 3 3,5 In-Segment MLD (mm) Intention to Treat
18 In-Segment Analysis (QCA) 25 Late Loss vs mm ,00 0,00 1,00 2,00 3,00 (mm) 2,50 2,00 1,50 EES DEB ( ) ( ) Kolmogorov-Smirnov <0.05 1,00 0,50 0,00-0,50 * p = ,00 0-1,00 0,00 1,00 2,00 3,00 * median (IQR); Mann-Whitney U QCA = CASS II System
19 Cumulative Frequency Distribution Curves 100 (%) POST p < RE 4 (4.7%) 8 (9.5%) p = 0.22 PRE 40 FU p < EES DEB In-Segment (%) Stenosis Intention to Treat
20 DEB vs BA in the RIBS trials (mm) MLD FU p < (mm) Late Loss p < BA RIBS I BA RIBS II DEB RIBS V BA RIBS I BA RIBS II DEB RIBS V (QCA) In-Segment Analysis
21 All Age >65y Female Diabetes UA Time RE (< 6Mo) LAD Vessel QCA (< 3mm) RE Length (>10mm) Edge ISR B/A > 1.1 * AMD= Absolute Mean Difference RIBS V 10 Pre-Specified Variables: (170) (96) (18) (42) (70) (54) (67) (132) (109) (12) (128) DEB Better MLD FU EES Better AMD * P Value All interactions (NS)
22 Events at Final FU (1 Year) 1 Year FU 189 P (100%); FU Time days MAE (Exclusive) MAE (Death, MI, TVR): Non-exclusive Events EES: 6 (6%) DEB: 11 (12%) p = 0.24 HR 0.55 (95%CI ) 10 5 p = 0.31 p = 0.68 p = Death* (4) AMI + (7) CABG (0) PCI TVR (8) * 3 Non Cardiac Deaths + 1 Definitive ST Thrombosis Intention to Treat
23 Clinical Follow-up: 1 Year FU 189 P (100%); FU Time days 100 % 94% Breslow, p = 0.65 Log Rank, p = 0.60 EES DEB 91% 20 Freedom from MACE (Cardiac Death, MI, TVR) Time (months)
24 Conclusions: In patients with BMS-ISR both DEB and EES provide excellent long-term clinical outcomes In this setting, DEB and EES also offer excellent late angiographic findings with a very low late loss and single digit restenosis rates (similar with both techniques) However, EES provide superior late angiographic results including MLD (1ry Endpoint) and % diameter stenosis Further studies (larger and with longer follow-up) are required to elucidate if these superior late angiographic findings eventually translate into a clinical benefit
EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent
Antonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,
Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting
LEADERS: 5-Year Follow-up
LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS
Retrieval Centres for HPC-M and HPC-A
A Coruña - (Cod: ES0061) COMPLEXO HOSPITALARIO UNIVERSITARIO JUAN CANALEJO Estrada das Xubias, s/n - 15006 Alcalá de Henares MADRID - (Cod: ES0208) HOSPITAL UNIV. PRINCIPE ASTURIAS Carretera Alcalá-Meco,
Cilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program
The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program Jean Fajadet, MD, FESC Clinique Pasteur - Toulouse - France Disclosure statement Nothing to disclose Dedicated Delivery
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France
The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.
The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,
Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands
Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting
OCT STEMI: OCT guidance during stent implantation
OCT STEMI: OCT guidance during stent implantation in primary PCI. A Randomized Multicenter study with 9-month optical coherence tomography follow-up Červinka P 1,2, Kala P 3, Jakl M 2,4, Kaňovský J 3,
Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam
Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital
Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI
Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos
Dialnet. Author Identification. Eduardo Bergasa eduardo.bergasa@unirioja.es
Dialnet Author Identification Eduardo Bergasa eduardo.bergasa@unirioja.es Fundación Dialnet! Public non-profit foundation! Spin-off of University of La Rioja! Constitution: 2009! In charge of Dialnet portal
OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent
Main Arena III - Plenary Sessions XVI Late Breaking Clinical Trials III - Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy
The BASE-ACS Trial. A Randomized Comparison of a TITAN-2 BAS with XIENCE-V- EES Stent in Acute Coronary Syndrome. 18 months Follow-up results
The BASE-ACS Trial A Randomized Comparison of a TITAN-2 BAS with XIENCE-V- EES Stent in Acute Coronary Syndrome 18 months Follow-up results Pasi Karjalainen, MD, PhD, adjunct Professor on behalf of the
Pooled RESOLUTE Clinical Program
The Relationship Between Short and Long-term Antiplatelet Therapy Use and Stent Thrombosis Following Percutaneous Coronary Intervention With the Resolute Zotarolimus-eluting Stent Pooled RESOLUTE Clinical
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
Clinical Programs. Medtronic Coronary Stent Systems. driver BMS
Clinical Programs Medtronic Coronary Stent Systems Endeavor DES driver BMS July 2010 Contents Overview of Clinical Programs... 2 Drug-Eluting Stents ENDEAVOR I*... 4 ENDEAVOR II*... 6 ENDEAVOR II Continued
MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
PRESENTATION OF E.164 NATIONAL NUMBERING PLAN COUNTRY CODE 34 SPAIN SHORT CODES. 0 3 3 Short codes Social value services
PRESENTATION OF E.164 NATIONAL NUMBERING PLAN COUNTRY CODE 34 SPAIN (Updated 01-10-2013) N(S)N number 00 2 2 International prefix SHORT CODES 0 3 3 Short codes Social value services 1 4 4 Short codes 103
University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
Is There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON
OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON - Baseline preliminary results - Takashi Akasaka, MD, PhD, FESC Wakayama Medical University,
Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada
Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada April 2009 Jack V. Tu, MD PhD FRCPC CANADA RESEARCH CHAIR IN HEALTH SERVICES RESEARCH Institute
Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)
Coronary Bifurcation Treatment: Update from the European Bifurcation Club Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Disclosure Statement of Financial Interest Within the past 12 months, I
OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS
OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS Division of Cardiology, Mount Sinai Hospital, New York, NY, USA Yuliya Vengrenyuk, PhD; and Annapoorna Kini, MD OCT ASSESSMENT OF CUTTING
Mattias Törnerud, Capio St Görans sjukhus AB, Stockholm. Invasiv tryckmätning FFR
Namn: Titel: Mattias Törnerud, Capio St Görans sjukhus AB, Stockholm Invasiv tryckmätning FFR Har mo/agit förläsararvoden från St Jude Medical. Intrakoronar tryckmätning, FFR i daglig praxis 1000 angio
GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES -
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.1 Appendix 1 December 2008 GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA
PCI vs. CABG for Left Main Disease
The EXCEL Ti Trial Design, Status, t and Timelines Gregg W. Stone, MD Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation PCI vs. CABG for Left Main Disease
Editorial. Adult Cardiology - Meta-analysis
Editorial Adult Cardiology - Meta-analysis Simple Versus Complex Bifurcation Stenting Strategies A Meta Analysis of Randomized Controlled Trials in the Drug Eluting Stent Era Ana Beatriz R. Medrano, MD
Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up
Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS
Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial
Polymer-Based, Paclitaxel-Eluting Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial Mark A. Turco, John A. Ormiston, Jeffrey J. Popma, Lazar Mandinov, Charles D. O'Shaughnessy, Tift Mann, Thomas
Cardiovascular disease has become a dominant cause of
Abstract Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman Panduranga Prashanth, Mohamed Mukhaini, Abdulla A. Riyami, Kadhim
Majestic Trial 12 Month Results
Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.
Déjeuner/Repas Débat ABBOTT «Docteur, je veux un stent qui se dissout» ABSORB,la révolu@on oui, mais chez quel pa@ent? Les dernières données ABSORB
Déjeuner/Repas Débat ABBOTT «Docteur, je veux un stent qui se dissout» ABSORB,la révolu@on oui, mais chez quel pa@ent? Les dernières données ABSORB Didier Carrié CHU Toulouse APPAC 4 Juin 2014 Aucun conflit
PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators
Polish-Italian-Hungarian Randomized ThrombEctomy Trial PIHRATE Trial On behalf PIHRATE investigators Dariusz Dudek MD, PhD Institute of Cardiology, Krakow, Poland Impact of distal embolization Distal embolization
Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos. Eulógio E Martinez
Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos Eulógio E Martinez IVUS vs luminologia Positivo Negativo estenose TCE oclusão CD sístole
The Bioresorbable Vascular Stent Dr Albert Ko
The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of
DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation
Original Contribution Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation Cynthia A. Yock, MS, J. Michael Isbill, MS, Spencer B. King III, MD, Mark
FFR CT : Clinical studies
FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity
Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the
Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI Thirty-Day and One-Year Outcomes of the BRIGHT Trial Yaling Han, MD, FACC On behalf of the BRIGHT investigators
06 Validation of risk prediction model
HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via
έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν
ΝΠθ ζζάθδκνσθϋ λδκν έΰκ μνεδν ιωθκ κεκη δεάμνι λδεάμ έΰζβν έκ,νσϊίί κν1γν λδζέκνβί1γ Α Α φ ; έζ δκμννένσθόμ ηί δεόμνκλ δκζόΰκμ, θν δ γθ άμνγνκλ /εάμ ΚζδθδεάμΝ λωεζδθδεάμν ένivus Scientific Director, Mediolanum
Clinical Results of Unprotected Left Main Coronary Stenting
Original Articles IMAJ VOL 11 MARCH 2009 Clinical Results of Unprotected Left Main Coronary Stenting Itsik Ben-Dor MD, Hana Vaknin-Assa MD, Eli Lev MD, David Brosh MD, Shmuel Fuchs MD, Abid Assali MD and
Perioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
Drug-Eluting Coronary Stents. Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate
Drug-Eluting Coronary Stents Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate Outline Coronary Artery Disease Evolution of Percutaneous Coronary Intervention
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
Main Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
HA Territory-wide PCI Audit 2003-05
HA Territory-wide PCI Audit 23-5 5 PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 26 Percutaneous Coronary Intervention Background HA AP target 2/3, coordinated by PCI Working
Review of Intracoronary Radiation for In-Stent Restenosis
Review of Intracoronary Radiation for In-Stent Restenosis Robert Lew, MBBS, FRACP, Andrew Ajani, MD, Ron Waksman, MD, FACC Vascular Brachytherapy using beta and gamma radiation is the standard care for
INTRODUCTION. Key Words:
Case Report Acta Cardiol Sin 2014;30:485 489 Successful Revascularization of Chronic Total Occlusion in Native Coronary Arteries through an Occluded Saphenous Bypass Vein Graft: A Retrograde Alternative
CARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD
CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ Charles White MD Director of Thoracic Imaging Department of Radiology University of Maryland CORONARY ARTERY BYPASS GRAFTS First performed
HPC authorized transplant centres SPAIN
Last updated: 8/1/08 A Coruña - (Cod: ES0061) COMPLEXO HOSPITALARIO UNIVERSITARIO JUAN CANALEJO Estrada das Xubias, s/n - 15006 ALBACETE - (Cod: ES0062) COMPLEJO HOSPITALARIO Y UNIVERSITARIO DE ALBACETE
Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,
Transcatheter Cardiovascular Therapeutics 19 th Annual Scientific Symposium October 20-25, 2007
Comparative Late Risk of Death, Myocardial Infarction, and Stent Thrombosis for Bare-Metal and Drug-Eluting Stents: A Landmark Analysis from the STENT Registry Charles Simonton MD, Bruce Brodie MD, Barrett
Prognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
ORIGINAL ARTICLES: Morphology and Location of Restenosis Following Bare Metal Coronary Stenting
Page 1 / 7 ORIGINAL ARTICLES: Morphology and Location of Restenosis Following Bare Metal Coronary Stenting - Marc J. Schweiger, MD, Ehsan Ansari, MD, Gregory R. Giugliano, MD, *James Mathew, MD, Ashequl
SAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014
Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
For the NXT Investigators
Diagnostic performance of non-invasive fractional flow reserve derived from coronary CT angiography in suspected coronary artery disease: The NXT trial Bjarne L. Nørgaard, Jonathon Leipsic, Sara Gaur,
None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
Z Grants & Donations for the first half of 2012- Patient Organization & Other Institutions Spain
Z Grants & Donations for the first half of 2012- Patient Organization & s Spain Payee Name Patient Organization Program/Project Description Support Type Contribution Type ACCION PSORIASIS Patient Association
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
Six versus Twelve Months of Clopidogrel Therapy After Drug-Eluting Stenting the Randomized, Double-Blind, Placebo-Controlled ISAR-SAFE Trial
Six versus Twelve Months of Clopidogrel Therapy After Drug-Eluting Stenting the Randomized, Double-Blind, Placebo-Controlled ISAR-SAFE Trial Stefanie Schulz-Schüpke, Julinda Mehilli, Karl-Ludwig Laugwitz,
Rotational Atherectomy for the Treatment of In-Stent Restenosis
Home SVCC Area: English - Español - Português Rotational Atherectomy for the Treatment of In-Stent Restenosis Steven L. Goldberg, MD Cardiac Catheterization Laboratory, University of Washington Medical
Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial
Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial Lucas Boersma, WimJan van Boven, Alaaddin Yilmaz, Johannes Kelder, Maurits Wijffels
Department of Haematology University Hospital. University of Salamanca, Spain
Immunophenotyping of Plasma Cells: Implications on management Department of Haematology University Hospital Cancer Research Centre J.F. San Miguel University of Salamanca, Spain Faculty disclosure information
Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents
Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents One-month results of the study Ida Riise Balleby 1, Trine Krejberg Ørhøj 1, Christian Juhl
on behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial
Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich
Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
Dual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes
Dual Antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents for Treatment of Acute Coronary Syndromes Robert W. Yeh, Dean J. Kereiakes, P. Gabriel Steg, Stephan Windecker, Michael J.
6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
Early And Late Outcome For Single Versus Double Stenting For Bifurcational Coronary Artery Lesions
ORIGINAL CONTRBUTION / CLINICAL INVESTIGATION Early And Late Outcome For Single Versus Double Stenting For Bifurcational Coronary Artery Lesions Aram J. Mirza Correspondence: Dr. Aram J.Mirza Interventional
La facilitazione alla PCI con statine
La facilitazione alla PCI con statine Bertinoro, 16 aprile 2010 Aldo Miola, M.D., Ph.D. Medical Manager Primary Care Pfizer Italy 1 Are statins beneficial in patients undergoing PCI? 2 3 Statin therapy
Status of Drug-Eluting Coronary Stents
Status of Drug-Eluting Coronary Stents EVOLUTION OF PERCUTANEOUS CORONARY INTERVENTIONAL TECHNOLOGIES The introduction of percutaneous transluminal coronary angioplasty (PTCA) in the late1970s provided
Validation of a Risk Score for Target Vessel Revascularization after Coronary Stent Implantation
Original Contribution Validation of a Risk Score for Target Vessel Revascularization after Coronary Stent Implantation a Alexandre S. Quadros, MD, PhD, b Fabiane Diemer, RN, b Dulce Welter, RN, Thais Modkowski,
Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.
DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
Registrations: www.doctaforum.com/gecp
Chair: Rafael Rosell Under the Auspices of: Registrations: www.doctaforum.com/gecp Thursday, 21 st of November 2013 08:00-10:00 CLINICAL SESSION Isabel lbover Fundación Hospital Son Llàtzer, Palma de Mallorca
High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent
High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent Masahiko Hara, MD, Masami Nishino, MD, Masayuki Taniike,
ADenosine Vasodilator Independent Stenosis Evaluation II
ADenosine Vasodilator Independent Stenosis Evaluation II A prospective, observational, non-randomized, double blind, global, multi-center registry with an adaptive design, investigating the diagnostic
Thursday, 20th November
Thursday, 20th November 10.30-10.45 Opening remarks Carlos Camps, Hospital General Universitario, Valencia Past, present and future of the Spanish Lung Cancer Group SESSION 1 Cancer biology and lung cancer
Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice
Interventional Cardiology Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice Jean-Jacques Goy, MD, a Philip Urban, MD, b Urs Kaufmann,
StentViz Enhanced Stent Visualization
GE Healthcare StentViz Enhanced Stent Visualization Dr. Morice, Dr. Lefèvre, Dr. Hovasse, Dr. Chevalier, Dr. Louvard Institut Cardiovasculaire Paris Sud, Massy, France Assessing the deployment of stents
Vascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial
Vascular Quality Initiative - Carotid Artery Stent Last Name First Name Middle Initial Date of Birth Medical Record Social Security General Information Patient Data Zip/Postal Code Gender Male Female Ethnicity
Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases
Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases T. Masood,T. Sagheer,D. Jan,N. Qamar,A.M.A. Faruqui ( National Institute of Cardiovascular Diseases (NICVD), Karachi.
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
ESC PCI Guidelines: / Sigmund Silber et al. 1
For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction
Percutaneous Transluminal Angioscopy during Coronary Intervention
Diagnostic and Therapeutic Endoscopy, Vol. 7, pp. 15--20 Reprints available directly from the publisher Photocopying permitted by license only (C) 2000 OPA (Overseas Publishers Association) N.V. Published
JUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JUL 2 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,